Patents by Inventor David Calabrese

David Calabrese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12434172
    Abstract: Systems and methods for managing fluid flow in and evaporating solvents from containers are provided. In various embodiments, systems of the present disclosure provide for cap or cover members operable to be provided with vials or containers comprising one or more fluids. The caps are further operable to direct air and gas flow into and out of the containers. In some embodiments, supporting structures and heating elements are provided to enhance and assist various processes.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: October 7, 2025
    Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Alexander Glenn Godfrey, Pranav Bende, Linus Eric Wallgren, David Calabrese
  • Patent number: 11898154
    Abstract: Disclosed are constructs and methods for expressing DNAs of interest in particular in non-primate eukaryotic host cells that display advantages with regard quantity and quality of expression including high stability of expression and, if appropriate, transport of the expression product out of the cell.
    Type: Grant
    Filed: February 1, 2014
    Date of Patent: February 13, 2024
    Assignee: SELEXIS S.A.
    Inventors: Valerie Le Fourn, Nicolas Mermod, Alexandre Regamey, Montse Buceta, Deborah Ley, Niamh Harraghy, Kaja Kostyrko, Pierre-Alain Giro, David Calabrese
  • Publication number: 20230193341
    Abstract: A transcriptomic analysis of genes consistently upregulated in high producer clones were each evaluated for their ability to increase the production of a protein of interest. The products of these genes (metabolism influencing products (MIP)), such as actin, Erp27, Erp57, Foxa1, PPAR, Ca3, and Tagap, could be sub-categorized into different functional categories such as signaling, protein folding, cytoskeleton organization and cell survival.
    Type: Application
    Filed: October 23, 2019
    Publication date: June 22, 2023
    Applicant: Selexis SA
    Inventors: Lucille Pourcel, Audrey Berger, Valerie Le Fourn, Severine Fagete, David Calabrese, Alexandre Regamey, Nicolas Mermod, Fabien Palazzoli, Pierre-Alain Girod
  • Publication number: 20230046668
    Abstract: Disclosed are cells that have stably integrated into their genomes exogenous nucleic acid sequences, such as transgenes, within or proximal to the integration site of a sequence comprising at least part of an endogenous retrovirus (ERV) or a LTR-retrotransposon (LTR-RT), or instead of a sequence encompassing an ERV or a LTR-RT that is part or was part of the genome of the cell, as well as method of producing and using such cells. Advantageously, a high level and/or stable production of the transgene expression product(s) can be achieved. Transgene integration and expression may be furthered by modulating the DNA repair pathways of the cell, e.g., by transiently expressing a gene encoding a protein that forms part of a DNA repair pathway during transgene integration.
    Type: Application
    Filed: December 24, 2020
    Publication date: February 16, 2023
    Applicant: Selexis S.A.
    Inventors: Pierre-Olivier Duroy, Alexandre Regamey, Ghislaine Arib, Valerie Le Fourn, David Calabrese, Pierre-Alain Girod
  • Publication number: 20220177546
    Abstract: The present disclosure provides production systems and host cells to produce collagen 7 compositions comprising recombinant collagen 7 and/or functional variants thereof. The host cells are genetically engineered to stably express rCol7 and functional variants thereof. The collagen 7 composition can be used to restore collagen 7 levels in a subject in need, and for preventing, preventing the progression of, alleviating, and delaying the on-set of a skin condition, e.g., skin wound associated with dystrophic epidermolysis bullosa (DEB).
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Inventors: Mark Desouza, Malini Viswanathan, Pierra-Alain Girod, Alexandre Regamey, Valerie Le Fourn, David Calabrese, John Gill, Megan Gottlieb, Amie Lundquist, Anna Tchoudakova, George Enriquez, Rahul Chelikani, Thomas Gagliardi, Tatiana Laivins, Hang Yuan
  • Publication number: 20210261516
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 26, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Yale University
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Patent number: 11014902
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: May 25, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Publication number: 20200308128
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: March 30, 2020
    Publication date: October 1, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Patent number: 10669562
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 2, 2020
    Assignee: SELEXIS S.A.
    Inventors: Nicolas Mermod, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Publication number: 20200109421
    Abstract: Disclosed herein are methods of genome alteration, in particular genome editing in eukaryotic cells (e.g., mammalian cells), preferably, but not exclusively the integration of exogenous nucleic acids into the genome of a cell or a population of cells. Such methods include the modulation of cell cycle phases via external conditions such as physical separation, temperature, exposure to certain substances such as cell cycle modulators. Genome alteration is also effected via the use of enzymes such as nucleases and nickases and/or the modulation of DNA repair pathways.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 9, 2020
    Applicant: Selexis S.A.
    Inventors: Valerie Le Fourn, Severine Fagete, Alexandre Regamey, David Calabrese, Ghislaine Arib, Pierre-Alain Girod
  • Patent number: 10604499
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 31, 2020
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Service
    Inventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Publication number: 20190100503
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 4, 2019
    Applicants: The United States of America as represented by the Secretary, Department of Health and Human Service, Yale University
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Patent number: 10196372
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: February 5, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Yale University
    Inventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Patent number: 10140776
    Abstract: Altering properties of rendered objects and/or mixed reality environments utilizing control points associated with the rendered objects and/or mixed reality environments is described. Techniques described can include detecting a gesture performed by or in association with a control object. Based at least in part on detecting the gesture, techniques described can identify a target control point that is associated with a rendered object and/or a mixed reality environment. As the control object moves within the mixed reality environment, the target control point can track the movement of the control object. Based at least in part on the movement of the control object, a property of the rendered object and/or the mixed reality environment can be altered. A rendering of the rendered object and/or the mixed reality environment can be modified to reflect any alterations to the property.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: November 27, 2018
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventors: Julia Schwarz, Bharat Ahluwalia, David Calabrese, Robert C J Pengelly, Yasaman Sheri, James Tichenor
  • Publication number: 20180187229
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Application
    Filed: December 19, 2017
    Publication date: July 5, 2018
    Applicant: SELEXIS S.A.
    Inventors: Nicolas Mermod, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Publication number: 20180030018
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: January 5, 2016
    Publication date: February 1, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Yale University
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Patent number: 9879297
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: January 30, 2018
    Assignee: SELEXIS SA
    Inventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Publication number: 20170358144
    Abstract: Altering properties of rendered objects and/or mixed reality environments utilizing control points associated with the rendered objects and/or mixed reality environments is described. Techniques described can include detecting a gesture performed by or in association with a control object. Based at least in part on detecting the gesture, techniques described can identify a target control point that is associated with a rendered object and/or a mixed reality environment. As the control object moves within the mixed reality environment, the target control point can track the movement of the control object. Based at least in part on the movement of the control object, a property of the rendered object and/or the mixed reality environment can be altered. A rendering of the rendered object and/or the mixed reality environment can be modified to reflect any alterations to the property.
    Type: Application
    Filed: June 13, 2016
    Publication date: December 14, 2017
    Inventors: Julia Schwarz, Bharat Ahluwalia, David Calabrese, Robert CJ Pengelly, Yasaman Sheri, James Tichenor
  • Publication number: 20150361451
    Abstract: Disclosed are constructs and methods for expressing DNAs of interest in particular in non-primate eukaryotic host cells that display advantages with regard quantity and quality of expression including high stability of expression and, if appropriate, transport of the expression product out of the cell.
    Type: Application
    Filed: February 1, 2014
    Publication date: December 17, 2015
    Inventors: Valerie Le Fourn, Nicolas Mermod, Alexandre Regamey, Montse Buceta, Deborah Ley, Niamh Harraghy, Kaja Kostyrko, Pierre-Alain Giro, David Calabrese
  • Publication number: 20130143264
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Application
    Filed: June 28, 2012
    Publication date: June 6, 2013
    Applicant: SELEXIS SA
    Inventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini